13F Holdings
中文EN

TGTX TG THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1001316 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY68.8%
TTM net income YoY-76.3%
TTM EPS YoY-75.8%
Revenue 3-yr CAGR67.9%
Net income 3-yr CAGR—

Margins

Gross margin82.7%
Operating margin21.5%
Net margin11.8%
FCF margin9.5%
EBITDA margin21.5%

Returns

ROE18.0%
ROA8.1%
ROIC (approx.)16.4%
Asset turnover0.69x

Leverage & solvency

Liabilities / assets64.1%
Debt / equity1.30x
Current ratio4.50x
Interest coverage4.14x

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio1.5%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$616.29M$329.00M$233.66M$2.79M$6.69M
Cost of revenue$100.71M$38.49M$14.13M$265,000$790,000
Gross profit$515.57M$290.52M$219.53M$2.52M$5.90M
R&D expense$160.22M$94.29M$76.19M$125.35M$222.58M
SG&A expense$232.03M$154.30M$122.71M$95.48M$128.09M
Operating income$123.32M$41.93M$20.63M-$218.32M-$344.77M
Interest expense$26.73M$24.03M$12.62M$10.19M$5.64M
Pretax income$107.39M$25.59M$13.06M-$223.81M-$348.10M
Income tax-$339.79M$2.21M$390,000$0$0
Net income$447.18M$23.38M$12.67M-$223.81M-$348.10M
EBITDA$123.38M$42.00M$20.84M-$218.01M-$344.49M
EPS (basic)3.100.160.09-1.65-2.63
EPS (diluted)2.770.150.09-1.65-2.63
Weighted avg. shares (diluted)161.41M160.34M148.51M135.41M132.22M
Balance sheet
Cash & equivalents$79.15M$179.89M$92.93M$102.30M$298.89M
Short-term investments$62.82M$131.11M$124.58M$59.37M$15.88M
Receivables$305.63M$129.19M$51.09M$0$1.39M
Inventory$125.59M$110.46M$39.82M$0—
Current assets$630.76M$566.36M$317.94M$168.27M$330.96M
PP&E, net——$95,000$307,000$600,000
Goodwill——$799,000$799,000$799,000
Total assets$1.06B$577.69M$329.59M$193.57M$379.63M
Current liabilities$153.76M$90.68M$53.72M$53.20M$65.38M
Short-term debt———$0$975,000
Long-term debt$245.65M$244.43M$100.12M$71.14M$66.79M
Total debt$245.65M$244.43M$100.12M$71.14M$67.76M
Total liabilities$415.23M$355.33M$169.09M$134.99M$142.48M
Shareholders' equity$648.02M$222.36M$160.50M$58.59M$237.15M
Net debt$166.50M$64.53M$7.18M-$31.17M-$231.12M
Shares outstanding155.31M155.84M151.42M146.39M143.25M
Cash flow statement
Operating cash flow-$24.77M-$40.52M-$31.41M-$176.17M-$295.63M
Capital expenditure$214,000$45,000$0$14,000$401,000
Free cash flow-$24.99M-$40.56M-$31.41M-$176.18M-$296.04M
Investing cash flow$13.80M-$1.04M-$50.65M-$20.01M-$332,000
Financing cash flow-$89.73M$128.53M$72.70M-$391,000$41.42M
Depreciation & amortization$59,000$68,000$211,000$303,000$282,000
Stock-based compensation$64.67M$42.54M$37.93M$44.66M$61.27M

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.